HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

copper-67-2IT-BAT-Lym-1

Subscribe to New Research on copper-67-2IT-BAT-Lym-1

a copper-67 radiopharmaceutical; Lym-1 is murine anti-lymphoma IgG2a antibody

Also Known As:

(67)Cu-(2-iminothiolane)-(6-(p-(bromoacetamido)benzyl)-1,4,8,11-tetra-azacyclotetradecane-N,N',N'',N'''-tetraacetic acid)-Lym-1 conjugate; 67Cu-2IT-BAT-Lym-1

Networked: 9 relevant articles (2 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Xiong, C Y: 1 article (06/2001)
2.	DeNardo, G L: 1 article (06/2001)
3.	Shi, X B: 1 article (06/2001)
4.	Winthrop, M D: 1 article (06/2001)
5.	Kroger, L A: 1 article (06/2001)
6.	Mack, P C: 1 article (06/2001)
7.	DeNardo, S J: 1 article (06/2001)
8.	Gumerlock, P H: 1 article (06/2001)
9.	Leshchinsky, T: 1 article (06/2001)
10.	Denardo, S J: 1 article (09/2000)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2001 - "67Cu-2IT-BAT-Lym-1 RIT induced an overall response rate of 50% with tolerable toxicity, and 29% of the tumors were cured at cumulated tumor radiation doses of about 1800 cGy. " 12/15/1997 - "The tumor uptake and radiation dose after 67Cu-2IT-BAT-Lym-1 were about two times greater when a single dose of rIL-2 was added: This may be the basis for enhanced therapeutic efficacy. " 12/15/1997 - "In mice treated with 335 microCi of 67Cu-2IT-BAT-Lym-1 alone, 28% of tumors were cured. " 06/01/2001 - "In preclinical and clinical trials, 67Cu-2IT-BAT-Lym-1 has shown an exceptionally long tumor residence time associated with substantial cumulated radiation doses. " 10/01/1999 - "67Cu-2IT-BAT-Lym-1 has been used in preclinical and clinical trials, where an exceptionally long residence time of 67Cu on tumor was observed. "
2.	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/01/1999 - "Encouraged by the results of 131I-Lym-1 therapy trials for patients with B-cell non-Hodgkin's lymphoma (NHL), this phase I/II clinical trial of 67Cu-2IT-BAT-Lym-1 was conducted in an effort to further improve the therapeutic index of Lym-1-based radioimmunotherapy. " 12/01/1999 - "A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma." 07/01/1998 - "Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study." 03/01/1999 - "In conclusion, 67Cu-2IT-BAT-Lym-1 given to non-Hodgkin's lymphoma patients in close temporal proximity to 131I-Lym-1 exhibited greater uptake and longer retention in tumor, resulting in higher radiation dose and therapeutic index than 131I-Lym-1. " 09/01/2000 - "Prior clinical trials proved that all histologic grades of chemotherapy-resistant B-cell non-Hodgkin's lymphoma (NHL) could respond to radio-immunotherapy (RIT) with 131I-Lym-1 and 67Cu-2IT-BAT-Lym-1. "
3.	Lymphoma (Lymphomas) 02/15/1995 - "Trial therapy for lymphoma with the radiolabeled chelate-antibody conjugate 67Cu-2IT-BAT-Lym-1 has been promising. " 10/01/1999 - "Effect of 67Cu-2IT-BAT-Lym-1 therapy on BCL-2 gene and protein expression in a lymphoma mouse model." 06/01/2001 - "The goal of this study was to examine Raji lymphoma xenografts for induction of apoptosis and modulation of apoptosis-related gene and protein expression in response to 67Cu-2IT-BAT-Lym-1 RIT. " 06/01/2001 - "In these therapy-resistant, human lymphoma tumors treated with 67Cu-2IT-BAT-Lym-1, apoptosis was convincingly demonstrated to be a major mechanism for the effectiveness of RIT and occurred by p53-independent mechanisms." 02/01/1999 - "67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma."
4.	Burkitt Lymphoma (Burkitt's Lymphoma) 12/15/1997 - "Enhancement of 67Cu-2IT-BAT-LYM-1 therapy in mice with human Burkitt's lymphoma (Raji) using interleukin-2."

Related Drugs and Biologics

1.	Interleukin-2 (IL2)

Related Therapies and Procedures

1.	Radioimmunotherapy
2.	Heterologous Transplantation (Xenotransplantation)
3.	Immunotherapy
4.	Drug Therapy (Chemotherapy)